Alcami will provide services for Trevena’s OLINVYK (oliceridine) injection, an opioid approved for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.
Alcami, a US-based contract development and manufacturing organization, announced on Aug. 26, 2020 that it will provide commercial manufacturing services for Trevena’s OLINVYK (oliceridine) injection, an opioid approved for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.
“For Alcami, this is another example of our ability to partner with customers to provide comprehensive support services from development through commercial approval," said Walt Kaczmarek, CEO of Alcami, in the press release. "We congratulate Trevena on their novel product offering and important advancement in pain therapy and are proud to offer our expertise and support.”
Source: Alcami
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.